The annual Metastatic Breast Cancer Conference, now in its fifth year, is scheduled for Nov. 15-16 in Baltimore, Maryland.

Allscripts, the Chicago-based electronic health record (EHR) company, has confirmed it is offering buyouts to employees, according to reporting from POLITICO.

Researchers at the University of British Columbia have developed a “smart stent” that can monitor hemodynamic changes in the artery and warn clinicians of restenosis at its earliest stages.

Diabetes advocates and legislators on both sides of the aisle are calling for more transparency and government oversight in the insulin market because of skyrocketing costs.

Concurrent chemoradiation therapy is the standard of care for patients with inoperable non-small cell lung cancer (NSCLC), but starting the dual treatments more than three days apart from each other can result in poorer overall survival and an 8 percent increased risk of death, according to research published in Clinical Lung Cancer this summer.

CMS is requesting input in hopes of “reducing the regulatory burdens” of the Stark Law, which prohibits physicians from referring Medicare or Medicaid beneficiaries to entities from which the physician or an immediate family member would financially benefit.

A wireless device was comparable to cardiac MRI in accuracy when detecting heart dysfunction in childhood cancer survivors who were treated with anthracycline chemotherapy, according to a study published in Clinical Cancer Research.

DUBLIN—June 21, 2018—Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of the MiniMed(TM) 670G system in patients with type 1 diabetes seven years of age and older.

More radiology practices reported that one of their radiologists utilized the Family and Medical Leave Act (FMLA) in 2016 than 2015, according to a new study published in the American Journal of Roentgenology. The authors noted, however, that the bump was not statistically significant.

Heart failure patients treated at hospitals with lower 30-day mortality rates also enjoy a survival benefit one, three and even five years later, suggesting a short-term risk-standardized mortality rate (RSMR) may deserve additional weight in CMS’s financial incentive programs.